A carregar...
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo
BACKGROUND: Solitomab is a novel bispecific single-chain antibody which targets EpCAM on tumor cells and also contains a CD3 binding region. We evaluated in vitro activity of solitomab against primary chemo-resistant epithelial ovarian carcinoma cell lines as well as malignant cells in ascites. METH...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4304922/ https://ncbi.nlm.nih.gov/pubmed/25251053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29062 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|